Stroke overall program provider Warby Medical completed hundreds of millions of dollars in round C financing

Sina Pharma was first informed that Warby Medical has recently completed more than hundreds of millions of yuan of C-round financing, led by Gao Gao Ventures, Innovation Workstation, Songbai Capital and Investment, Golu Capital as the exclusive financial adviser.
will be used for the company's core products, as well as stroke products listed at home and abroad.
that Warby Healthcare had just completed its last round of funding in August.
There is huge room for stroke market, and Worby pioneered the global market for stroke to be the leading cause of death in China, with 5.67 million people discharged from public hospitals for cerebrovascular disease in 2018, including more than 720,000 people with intracranial hemorrhage, 3.73 million with cerebral infarction, cerebral artery closure and stenosis of 87,000, according to the 2019 Health Statistics Yearbook.
stroke has the characteristics of high mortality and high disability rate, and it is of great social significance to treat stroke patients in time to save lives and reduce the occurrence of disability.
the domestic neural intervention industry is still in its early stages of development, in 2019 China's mechanical thrombosis treatment of acute ischemic stroke penetration rate of only about 1.18%.
with the increase in treatment penetration and the release of grass-roots demand, the industry ushered in a period of rapid development, China's potential market space of 30 billion yuan, is the most growth of domestic innovative equipment segment track.
stroke can be divided into ischemic and hemorrhagic two categories, Worby Medical at the same time layout of these two areas, product pipeline is rich, including spring rings, thrombosis straw, hydrant stent, mesh bracket, balloons, wire guide and other heavy products.
spring rings and suction catheters to become the company's fastest-growing products.
Wobi Medical Avenir™ mechanical free spring ring has completed domestic clinical trials, and passed the National Drug Administration's application for special examination of innovative medical devices, is the field so far the only access to the special examination procedures "green channel" products, is expected to be listed in the domestic forensics next year.
blood clot suction catheter, developed in-house for ischemic stroke, is another flagship product of Warby Medical.
pumping catheter mainly uses the principle of negative pressure suction to reach the near end of the blood vessel of thrombosis, the blood clot is sucked out.
currently, 80% of ischemic stroke devices in the U.S. market are used first to pump catheters, which are already considered the future trend of mechanical hydrants.
it is understood that Warby Medical is actively applying for the catheter's FDA and EU CE certification, domestic registration has been in and Xuanwu Hospital and other medical institutions to carry out clinical trials.
expects Toby's intermediate catheter products to go on sale in China in the first quarter of next year.